Boundless Bio, Inc. (NasdaqGS: BOLD)
Health Care · Biotechnology · US
$3.03
+3.06% today · +160.2% 1Y
Boundless Bio, Inc. (NasdaqGS: BOLD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $66.87M and employs 28 people.
Over the last twelve months the share price has gained 160.2%, trading between 0.96 and 3.16.
Tweenvest scores Boundless Bio, Inc. across four factors: quality 27/100. Its strongest factor is quality.
BOLD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $66.87M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.86
- Dividend yield
- —
- Beta (5Y)
- 0.38
- 52-week high
- $3.16
- 52-week low
- $0.96
- Avg volume (3M)
- —
- Shares outstanding
- 22.75M
- Employees
- 28
- Next earnings
- —
About Boundless Bio, Inc.
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
- ISIN
- US10170A1007
- Founded
- 2018
- Listed since
- Mar 28, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.